Perhaps because studying the proteome has become a crowded endeavor, an East German startup called MelTec has set its eyes on a new “ome:” the toponome. Determining all the structural networks that proteins form within a single cell — MelTec’s description of the toponome — and how their composition changes at different stages, will be more meaningful for drug discovery than just looking at differences in protein expression levels over an average of many cells, according to Walter Schubert, the company’s founder and CEO.